Once-daily treatment of pulmonary fibrosis

Abstract

A compound of formula (I) for use in a method for treatment of pulmonary fibrosis in a human including administering, with a dry powder inhaler, once-a-day to the narrowest parts of the lung tissue of the human an amount of the compound of formula (I) effective to treat the pulmonary fibrosis.

We claim: 
     
         1 . A method for treatment of pulmonary fibrosis in a human comprising administering once-a-day to the narrowest parts of the lung tissue of the human an amount of a compound of formula (I) 
       
         
           
           
               
               
           
         
       
       effective to treat said pulmonary fibrosis, wherein the administration is carried out by a dry powder inhaler. 
     
     
         2 . The method of  claim 1 , wherein the compound of formula (I) is bis (3-deoxy-3-(3-fluorophenyl-1H-1,2,3-triazol-1-yl)-β-D-galactopyranosyl)-sulfane as the free form. 
     
     
         3 . The method of  claim 1 , wherein the pulmonary fibrosis is Idiopathic pulmonary fibrosis (IPF). 
     
     
         4 . The method of  claim 1 , wherein the administration is carried out by a monodose dry powder inhaler, such as the RS01 Monodose Dry Powder Inhaler (Plastiape). 
     
     
         5 . The method of  claim 4 , wherein the monodose dry powder inhaler is a RS01 Monodose Dry Powder Inhaler. 
     
     
         6 . The method of  claim 1 , wherein the once daily amount is from 0.15 mg to 50 mg of the compound of formula I. 
     
     
         7 . The method of  claim 1 , wherein the treatment is chronic treatment. 
     
     
         8 . The method of  claim 1 , wherein the once daily amount is present in a suitable particle size selected from a mean mass aerodynamic diameter (MMAD) between 0.1 and 20 μm. 
     
     
         9 . The method of  claim 1 , wherein the compound of formula I is administered neat or together with a pharmaceutically acceptable additive. 
     
     
         10 . The method of  claim 9 , wherein the pharmaceutically acceptable additive is a carrier. 
     
     
         11 . The method of  claim 10 , wherein the carrier is lactose.